WallStreetZenWallStreetZen

AnalystsJennifer Kim
Jennifer Kim's Stock Forecasts

Analyst Ranking
Bottom 7%
#4285 out of 4563 analysts
Average Return
-20.69%
Win Rate
24%8 out of 34
Risk vs Reward
Poor
Good

Jennifer Kim's 5 best and worst ratings

Name / TickerGain/LossEntry PriceExit PricePeriodRating
Ocugen IncOCGN
+173.78%$0.43$1.18
2023-08-30 -
2024-04-24
Strong Buy
Eyepoint Pharmaceuticals IncEYPT
+109.28%$7.87$16.47
2023-06-27 -
2024-04-24
Strong Buy
Eyepoint Pharmaceuticals IncEYPT
+66.20%$9.91$16.47
2023-08-30 -
2024-04-24
Strong Buy
Belite Bio IncBLTE
+54.65%$24.10$37.27
2023-07-27 -
2024-04-24
Strong Buy
Eyepoint Pharmaceuticals IncEYPT
+49.73%$11.00$16.47
2023-09-13 -
2024-04-24
Strong Buy

Jennifer Kim Analyst Color

Get additional color on Jennifer Kim's coverage of popular stocks

Jennifer Kim's Stock Coverage

Name / TickerNo. RatingsRatingPrice TargetUpside/DownsideActionDate
Poseida Therapeutics IncPSTX
2Strong Buy$14.00+576.33%Reiterates
6 months ago
Insmed IncINSM
5Strong Buy$54.00+109.22%Maintains
7 months ago
Eyepoint Pharmaceuticals IncEYPT
4Strong Buy$31.00+88.22%Reiterates
7 months ago
Ocugen IncOCGN
2Strong Buy$2.00+69.49%Maintains
8 months ago
Fortress Biotech IncFBIO
2Strong Buy$75.00+4,089.94%Reiterates
8 months ago
Checkpoint Therapeutics IncCKPT
4Strong Buy$14.00+872.22%Maintains
8 months ago
Belite Bio IncBLTE
1Strong Buy$43.00+15.37%Initiates Coverage On
9 months ago
Lipocine IncLPCN
2Strong Buy$33.00+643.24%Reiterates
9 months ago
Proqr Therapeutics NvPRQR
2Strong Buy$4.50+123.88%Maintains
a year ago
Novan IncNOVNQ
2Strong Buy$8.00N/AReiterates
a year ago
Allakos IncALLK
3Strong Buy$7.00N/AReiterates
a year ago
Precigen IncPGEN
2Strong Buy$10.00N/AMaintains
a year ago
Aytu Biopharma IncAYTU
2Strong Buy$100.00N/AMaintains
2 years ago
Calcimedica IncCALC
1Strong Buy$4.00N/AMaintains
2 years ago
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.